Kaylene Simpson

Prof. Kaylene Simpson

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2006 in Nature
Verified
Journal Article
Closed access
PDF file
MSMark Shackleton
Mark Shackleton
FVFrançois Vaillant
François Vaillant
KSKaylene Simpson
Kaylene Simpson
JSJohn Stingl
John Stingl
GSGordon Smyth
Gordon Smyth
JVJane E. Visvader
Jane E. Visvader

10 August 2008 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
KSKaylene Simpson
Kaylene Simpson
LSLaura M. Selfors
Laura M. Selfors
JBJames Bui
James Bui
ARAngela Reynolds
Angela Reynolds
DLDevin Leake
Devin Leake
JBJoan S. Brugge
Joan S. Brugge

11 November 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DEDariush Etemadmoghadam
Dariush Etemadmoghadam
BWBarbara A. Weir
Barbara A. Weir
GAGeorge Au-Yeung
George Au-Yeung
KAKathryn Alsop
Kathryn Alsop
GMGillian Mitchell
Gillian Mitchell
DBDavid D. L. Bowtell
David D. L. Bowtell
Significance: Women with high-grade serous ovarian cancer (HGSC) harboring Cyclin E1 (CCNE1) gene amplification generally face a poor clinical outcome. These tumors comprise a significant group of ∼20% of HGSCs that are not associated withBRCA1/2mutation and are unlikely to respond to standard cytotoxic or poly-ADP-ribose polymerase inhibitors. We identified a specific dependency onBRCA1and members of the ubiquitin pathway inCCNE1-amplified tumors. The requirement forBRCA1seems to account for the mutual exclusivity of mutations observed in primary tumors. We propose a unique therapeutic strategy involving inhibition of the proteasome and homologous recombination function with bortezomib. Our findings are likely to have relevance to the treatment of other tumor types withCCNE1amplification, including triple negative breast cancer.

17 May 2021 in Cell
Verified
Journal Article
Closed access
SVStephin J. Vervoort
Stephin J. Vervoort
SWSarah A. Welsh
Sarah A. Welsh
JDJennifer R. Devlin
Jennifer R. Devlin
EBElisa Barbieri
Elisa Barbieri
DKDeborah A. Knight
Deborah A. Knight
RJRicky W. Johnstone
Ricky W. Johnstone

1 November 2012 in Cancer Cell
Verified
Journal Article
Closed access
GMGhassan Mouneimne
Ghassan Mouneimne
SHScott D. Hansen
Scott D. Hansen
LSLaura M. Selfors
Laura M. Selfors
LPLara Petrak
Lara Petrak
MHMichele M. Hickey
Michele M. Hickey
JBJoan Brigge
Joan Brigge

1 September 2009 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PSPeter Storz
Peter Storz
HDHeike Döppler
Heike Döppler
JCJohn A. Copland
John A. Copland
KSKaylene Simpson
Kaylene Simpson
ATAlex Toker
Alex Toker
The role of the Forkhead transcription factor FOXO3a in processes that promote tumor metastasis is poorly defined. Here, we show that depletion of FOXO3a from cancer cells leads to decreased tumor size specifically due to attenuated invasive migration. During tumor progression, an increase in tumor mass is concomitant with serum deprivation prior to tumor angiogenesis. We show that nuclear retention of FOXO3a due to serum starvation results in greatly increased cancer cell invasion. Exploration of the mechanism by which FOXO3a promotes invasive migration revealed that it induces the expression of matrix metalloproteinase 9 (MMP-9) and MMP-13, both of which have been causally linked to the invasion and progression of numerous human solid tumors. Our results link Forkhead transcription factors to a previously unexplored function in cancer progression by promoting extracellular matrix degradation, allowing tumors to invade neighboring tissues and ultimately metastasize to distant organs.